Shujing Zhang

4PUBLICATIONS
16CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersNutritional epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 16, 2023
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.

Shujing Zhang, Arielle G Bensimon, Ruifeng Xu

|Feb 07, 2023
Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland.

Andrea Favre-Bulle, Goran Bencina, Shujing Zhang

|Jan 18, 2023
Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.

Zev A Wainberg, Jipan Xie, Adriana Valderrama

|Oct 14, 2022
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.

Tingting Qu, Shujing Zhang, Yichen Zhong

Pageof 1

Frequent Collaborators

1 joint publications

Tingting Qu

1 joint publications

Zev A Wainberg

1 joint publications

Jipan Xie

1 joint publications

Adriana Valderrama